NSP-04 Managing infections, hypogammaglobulinemia, and neutropenia during treatment with teclistamab in relapsed/refractory multiple myeloma: nurse-led experience from the MajesTEC-1 study
Donna Catamero(Mount Sinai Health System), Sandy Kruyswijk(Amsterdam University Medical Centers), Keqin Qi(Janssen (United States)), Arnob Banerjee(Johnson & Johnson (United States)), Margaret Doyle(Janssen (Ireland)), Katherine Chastain(Janssen (United States)), Sheri Skerget(Translational Genomics Research Institute), Patricia Blázquez Benito(Universidad de Salamanca), Samantha Shenoy(University of California, San Francisco)
Cited by 0
Related Papers
Teclistamab in Relapsed or Refractory Multiple Myeloma
|New England Journal of Medicine|2022|1.2k
Ciltacabtagene Autoleucel, an Anti–B-cell Maturation Antigen Chimeric Antigen Receptor T-Cell Therapy, for Relapsed/Refractory Multiple Myeloma: CARTITUDE-1 2-Year Follow-Up
|Journal of Clinical Oncology|2022|647
Cutting Edge: The Transcription Factor Eomesodermin Enables CD8+ T Cells To Compete for the Memory Cell Niche
|The Journal of Immunology|2010|417